Robert Kramer Emergent Bio Solutions Inc. (EBS) insider trading activity

Robert Kramer is President and CEO of Emergent BioSolutions Inc.. Currently has a direct ownership of 506,059 shares of EBS, which is worth approximately $5.9 Million. The most recent transaction as insider was on Jun 09, 2023, when has been sold 212,308 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 506K

0% 3M change

0% 12M change

Total Value Held $5.9 Million

Robert Kramer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 09 2023	BUY Grant, award, or other acquisition	-	212,308 Added 29.55%	506,059 Common Stock
Mar 02 2023	BUY Grant, award, or other acquisition	-	57,693 Added 16.42%	293,751 Common Stock
Feb 28 2023	SELL Payment of exercise price or tax liability	$39,937 $12.38 p/Share	3,226 Reduced 3.03%	103,298 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$21,812 $13.71 p/Share	1,591 Reduced 1.47%	106,524 Common Stock
Feb 23 2023	SELL Payment of exercise price or tax liability	$20,420 $14.3 p/Share	1,428 Reduced 1.3%	108,115 Common Stock
Feb 08 2023	SELL Payment of exercise price or tax liability	$65,508 $13.25 p/Share	4,944 Reduced 4.32%	109,543 Common Stock
Feb 08 2023	BUY Grant, award, or other acquisition	-	278 Added 0.24%	114,487 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	89,415 Added 26.45%	248,684 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$67,983 $39.64 p/Share	1,715 Reduced 0.69%	246,969 Common Stock
Feb 24 2022	SELL Payment of exercise price or tax liability	$86,384 $42.47 p/Share	2,034 Reduced 1.26%	159,269 Common Stock
Feb 23 2022	SELL Payment of exercise price or tax liability	$59,924 $42.23 p/Share	1,419 Reduced 0.87%	161,303 Common Stock
Feb 22 2022	SELL Payment of exercise price or tax liability	$194,047 $42.23 p/Share	4,595 Reduced 2.75%	162,722 Common Stock
Feb 22 2022	BUY Grant, award, or other acquisition	-	4,264 Added 2.49%	167,317 Common Stock
May 08 2021	SELL Payment of exercise price or tax liability	$5,792 $61.62 p/Share	94 Reduced 0.06%	163,053 Common Stock
Feb 26 2021	SELL Payment of exercise price or tax liability	$250,258 $97.15 p/Share	2,576 Reduced 1.55%	163,147 Common Stock
Feb 24 2021	SELL Payment of exercise price or tax liability	$226,713 $93.49 p/Share	2,425 Reduced 1.44%	165,723 Common Stock
Feb 24 2021	BUY Grant, award, or other acquisition	-	29,950 Added 15.12%	168,148 Common Stock
Feb 09 2021	SELL Payment of exercise price or tax liability	$529,971 $123.45 p/Share	4,293 Reduced 3.01%	138,198 Common Stock
Feb 09 2021	BUY Grant, award, or other acquisition	-	3,281 Added 2.31%	138,621 Common Stock
Feb 08 2021	SELL Open market or private sale	$5,449,002 $120.03 p/Share	45,397 Reduced 24.59%	139,210 Common Stock
Feb 08 2021	BUY Exercise of conversion of derivative security	$1,395,958 $30.75 p/Share	45,397 Added 22.97%	152,210 Common Stock
Jan 21 2021	SELL Open market or private sale	$2,409,657 $110.03 p/Share	21,900 Reduced 13.59%	139,210 Common Stock
Jan 21 2021	BUY Exercise of conversion of derivative security	$579,255 $26.45 p/Share	21,900 Added 11.97%	161,110 Common Stock
Jan 20 2021	SELL Open market or private sale	$245,520 $110.0 p/Share	2,232 Reduced 1.58%	139,210 Common Stock
Jan 20 2021	BUY Exercise of conversion of derivative security	$59,036 $26.45 p/Share	2,232 Added 1.55%	141,442 Common Stock

Robert Kramer

President and CEO

Gaithersburg, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EBS shares.

Notify only if

Value

Insider Trading

Get notified when an Emergent Bio Solutions Inc. insider buys or sells EBS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Emergent BioSolutions Inc.

Track Activities on EBS

Account